Filing Details
- Accession Number:
- 0001209191-23-048632
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-09-07 16:31:22
- Reporting Period:
- 2023-09-05
- Accepted Time:
- 2023-09-07 16:31:22
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1851194 | Ventyx Biosciences Inc. | VTYX | Pharmaceutical Preparations (2834) | 832996852 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1875786 | Martin Auster | C/O Ventyx Biosciences, Inc. 12790 El Camino Real, Suite 200 San Diego CA 92130 | Chief Financial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2023-09-05 | 18,327 | $32.26 | 29,322 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2023-09-05 | 8,142 | $33.41 | 21,180 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2023-09-05 | 3 | $33.98 | 21,177 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 29, 2022.
- Represents the weighted average share price of an aggregate total of 18,327 shares sold in the price range of $31.97 to $32.8321. The reporting owner undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- Represents the weighted average share price of an aggregate total of 8,142 shares sold in the price range of $32.97 to $33.96. The reporting owner undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Billionaire Hedge Funds
